AstraZeneca sells US rights to RSV drug to Swedish firm for $1.5B
Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.
First new hairy cell leukemia drug in 20 years approved, but will it make a dent?
While AstraZeneca touted Lumoxiti as the first new therapy for HCL in 20 years, a leukemia expert downplayed the significance of the trial data that led to the approval.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
AstraZeneca, teaming with J. Craig Venter, is integrating genomics into every phase of its R&D
Working with J. Craig Venter's Human Longevity Inc, the Wellcome Trust Sanger Institute and Finland's Institute for Molecular Medicine, AstraZeneca — and its biologics R&D arm MedImmune — plans to integrate genomics research into every step of drug development.
Flu shot as Batman: Healthcare marketing hit or miss?
The new MedImmune vaccination is the big news for this year’s flu season – that and athena health stepping in while the CDC staff is furloughed. This new flu shot is supposed to protect against four strains instead of just one. MedImmune has to have a good sales pitch, in part because the vaccine is […]
Q2 Corporate VC healthcare deals, funding both up more than 30 percent
Corporate venture capital may be what fills in the large gaps VC has left behind, with CVC deals about 60 percent larger than VC deals on the whole. Healthcare corporate venture capital deals are up nearly 40 percent compared to Q1 and funding is up 34 percent, according to a report from CB Insights. There were […]
Yale spinoff licenses HER3 cancer drug from MedImmune, plans for Phase 1 trials in 2014
A cancer drug startup spun out of the Yale School of Medicine has licensed the rights to develop and test a drug candidate from MedImmune designed to target a receptor that’s been connected to various cancers including breast, lung, ovary and colon. Kolltan Pharmaceuticals hopes to have its lead candidate, which targets the HER3 receptor […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Early stage biotechs told to make early decisions to avoid late-stage failures
The CED Biotech/Life Science Conference didn’t have an official theme, but if it did, it could have been "think early." What the more than 1,000 in attendance got was a steady, instructional drumbeat telling them to think about facing important decisions for their companies and their research and development at earlier stages than they’re accustomed.